Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News PTC Therapeutics Inc PTCT

Healthcare Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central... see more

Current News (NDAQ:PTCT)

PTC Therapeutics Announces Health Canada Approval of Sephience(TM) (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

Canada NewsWire December 10, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire December 1, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

GlobeNewswire December 1, 2025

Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

PR Newswire November 24, 2025

PTC Therapeutics to Host R&D Day

PR Newswire November 20, 2025

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PR Newswire November 4, 2025

PTC Therapeutics to Participate at Upcoming Investor Conferences

PR Newswire October 31, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire October 27, 2025

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

PR Newswire October 21, 2025
View More News ››

Opinion & Analysis (NDAQ:PTCT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PTCT)

Buy this at the open

This stock is going to have a good run. Safe play and a prob double from this price. I think they will have news in the morning and may...
2PackHabbit - October 7, 2015
View more Bullboard ››

Atlas Salt Inc.

Atlas Salt Inc.

Atlas Salt Inc. engages in the evaluation, exploration and development of mineral properties in Newfoundland and Labrador ...
View More »

Podcasts